Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The goal of this trial was to explore the utility of evaluating emphysema progression through
CT scans measuring lung density during a 2 year period of weekly infusions of either placebo
or human alpha-1-antitrypsin (AAT; Prolastin®). Exacerbation data recorded in patient diaries
were also collected. All efficacy data were analyzed for potential use in evaluating
Prolastin efficacy in this and other clinical trials.
Phase:
Phase 2
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC
Treatments:
Alpha 1-Antitrypsin Protease Inhibitors Protein C Inhibitor